A return of bacterial vaginosis (BV) symptoms after treatment can be frustrating, but it does not automatically justify refilling an old metronidazole prescription. Recurrent BV raises a new set of clinical questions: was the earlier diagnosis correct, did symptoms fully resolve, is another infection involved, and would the person benefit from a different acute treatment or a longer-term suppressive plan? CDC recognizes recurrence as common and provides limited-evidence options for patients with multiple episodes.
Metronidazole may appear in both ordinary treatment and selected recurrence-prevention strategies, but those strategies are not interchangeable. A standard course of oral tablets and intermittent vaginal gel prescribed over several months are very different exposures and pharmacy orders. A clinician must evaluate whether an extended approach fits the individual circumstance, including pregnancy concerns, tolerability and the likelihood of another diagnosis. See the first-episode BV guide for the usual treatment framework.
This page explains the recurrence-specific decision process, how guideline-based suppression differs from routine FDA-labeled product use and what a legitimate pharmacy needs for any repeat prescription. It does not instruct readers to begin maintenance therapy themselves or claim a permanent cure. For product identity, consult the 0.75% vaginal gel reference; for actual refills, the vaginal prescription guide is the appropriate next step.
CDC guidance distinguishes a first recurrence from multiple recurrences because the strength of available evidence and the possible management approaches differ. After one return of BV, a clinician might consider repeating a recommended regimen or selecting another recognized option. Multiple episodes can lead to discussion of suppressive vaginal therapy. Neither scenario proves that a person should repeatedly take antibiotics without a new evaluation.
A symptom diary can help the clinician identify whether there are symptom-free intervals, whether previous treatment was completed and whether symptoms could represent yeast infection, an STI or noninfectious irritation. Exact labels matter: an episode documented by clinical examination differs from a presumed recurrence diagnosed only by smell. A current assessment is particularly important if pain, fever or pregnancy-related symptoms are present.
Abnormal discharge or irritation may reflect BV, candidiasis, trichomoniasis or cervicitis, which can overlap. A clinician may use vaginal pH, microscopy, appropriate NAAT testing or other assessments to clarify the cause of symptoms. Treating every recurring symptom as BV can delay identification of another condition and generate unnecessary antimicrobial exposure.
If a previous prescription was ineffective, the treating professional needs to know exactly which drug, route and course was used and whether the patient was able to complete it. An old pharmacy label is useful background, not automatic authorization for a fresh course. See trichomoniasis-specific guidance for a condition with different partner and treatment rules.
For people with multiple recurrences, CDC reports that twice-weekly 0.75% metronidazole vaginal gel for longer than three months can reduce recurrence while therapy continues, although protection may not persist when suppression is stopped. This is a clinician-directed recurrence strategy described in treatment guidance, not a reason to use any gel repeatedly. The prescribing clinician decides the exact course and whether off-label use is involved.
Some more complex approaches combine different treatment stages, including oral treatment followed by other vaginal interventions and suppression. Their supporting evidence is limited and the ingredients are not interchangeable. Public descriptions of those protocols should not be interpreted as instructions to obtain all components without clinical supervision.
| Clinical situation | What may be considered | What cannot be assumed |
|---|---|---|
| Symptoms return for the first time | Confirm diagnosis; clinician may use a recommended regimen again | Automatically prolonged metronidazole is necessary |
| Multiple confirmed recurrences | Review suppressive vaginal therapy under clinician direction | Suppression cures BV permanently |
| Symptoms are atypical or accompanied by STI risks | Different diagnostic testing and follow-up | Every episode is BV |
| An old prescription is still on file | Verify if it has any legal refills and whether reassessment is needed | A previously used antibiotic can be repeated independently |
Suppressive metronidazole vaginal gel may reduce BV episodes while it is being used, but recurrence can still occur after suppression stops. Evidence for maintenance therapy and evidence for treating an ongoing sexual partner address different parts of recurrence management. The CDC 2021 guideline focuses on recurrence regimens and reflects older evidence on partner care. ACOG 2025 and New York State 2026 guidance address more recent randomized-trial evidence that concurrent partner therapy can reduce recurrence in some populations.
A realistic plan includes a review point: how to assess response, when follow-up should occur and what to do if symptoms recur during or after suppression. The patient should understand both possible benefit and the uncertainty. Anyone experiencing new symptoms should check with the clinician rather than increasing frequency of use or buying another product online.
Partner management is an area where clinical guidance changed. The 2021 CDC STI guidelines stated that routine partner treatment was not recommended on the basis of trials then available. A subsequent randomized trial using concurrent oral and topical antibiotic treatment for ongoing male partners reported fewer BV recurrences among treated couples; this prompted an October 2025 ACOG practice update. ACOG now supports considering concurrent treatment for male partners of adults with recurrent symptomatic BV and shared decision-making for selected other partnerships. The guidance does not turn BV into the same diagnosis as trichomoniasis.
New York State guidance issued in February 2026 explains how clinicians may assess ongoing partners and why the evidence is not equally established in every population or relationship arrangement. The regimen studied for male partners combined oral and topical medicines; a vaginal prescription for one person must not simply be handed to another person or applied to a different body site without a clinician’s specific authorization. Whether treating a partner, prescribing suppression or assessing recurrent symptoms, separate evaluation and medication counseling are essential.
The Australian StepUp study enrolled a particular population of adult heterosexual couples and tested treating a woman with symptomatic BV together with an ongoing male partner. Partner therapy combined oral and topical antimicrobial agents, unlike previous trials that largely examined oral medication alone. The trial reported substantially lower BV recurrence over the observed follow-up period, but its participants and follow-up window limit assumptions about all populations or lifelong protection.
Clinical choices for same-sex partnerships, multiple partners, pregnancy, allergy and other circumstances may require additional judgment because supporting evidence differs. ACOG recommends shared decision-making in these areas, not automatic dispensing. Patients can bring the relevant partner history to a visit and ask whether a partner should receive an independent evaluation, while the prescriber considers concurrent treatment, suppression and testing for other causes of recurrent symptoms.
| Question | Supported interpretation | What not to infer |
|---|---|---|
| What changed in 2025? | ACOG recognized evidence supporting concurrent partner therapy in selected recurrent BV | Every BV case requires partner antibiotics |
| What was studied? | Concurrent oral-plus-topical care for ongoing male partners in a defined trial population | Any one oral drug alone has the same demonstrated effect |
| What about other partnerships? | Discuss evidence limitations and patient preferences with a clinician | Evidence is equally strong for all partner groups |
| Can patients share medicine? | No; independent evaluation and appropriate prescriptions are needed | A partner can use a vaginal or oral prescription written for someone else |
The prescribed route, concentration, quantity, frequency and duration must all be transmitted to the pharmacy. Standard 0.75% vaginal gel is different from Nuvessa 1.3% single-dose gel and from 0.75% dermal rosacea gel. Concentration and route matching are essential, and one package cannot be considered an approved substitute simply because it contains metronidazole.
Insurance may review an extended or off-label regimen differently from an ordinary acute BV prescription. Ask about the exact quantity, coverage restrictions and authorization requirements, while leaving treatment design to the clinician. The vaginal gel pricing guide can help frame the financial questions without relying on current pharmacy offers.
Some prescriptions allow an authorized refill, but a claim for more medication should never be taken as evidence that repeated treatment is clinically right. The clinician may need to assess recurrent symptoms before writing a new order. At the pharmacy, the patient should clarify whether a new prescription is required and whether the dispensed package matches the clinician's current plan.
If a maintenance prescription is issued, use the pharmacist's counseling about the particular product and follow the prescribed instructions. Do not continue a suppressive course indefinitely by assuming that a longer supply is always better. The central goal is coordinated recurrence management, not rapid antibiotic purchasing.
Seek review if symptoms worsen, fail to improve, recur frequently or present differently from earlier episodes. Fever, pelvic pain and other systemic concerns may call for more urgent evaluation and testing. Pregnancy also warrants individualized assessment rather than relying on a previously effective regimen.
Bring previous treatment dates, drug names, test results if available and questions about side effects or interactions. This record can help the clinician distinguish a true recurrent pattern from misdiagnosis or another infection. It is a better starting point than ordering a larger quantity of metronidazole on speculation.
BV can recur because vaginal microbial communities and other contributing factors may change again. Recurrence does not by itself prove that the initial medicine was ineffective or should be repeated without reassessment.
Not automatically. A clinician may consider repeating an established regimen after an initial recurrence, but the diagnosis and current circumstances should first be assessed.
CDC describes clinician-directed intermittent 0.75% vaginal gel for some people with multiple recurrences. The regimen and any off-label aspects require professional oversight.
No. CDC notes that reduced recurrences during suppressive therapy may not persist after treatment stops.
A single-dose branded gel is not interchangeable with a regimen involving 0.75% vaginal gel. Never substitute the products independently.
Yes. Similar symptoms can result from yeast infection, trichomoniasis, cervicitis or other conditions. Testing may be needed.
Not automatically. ACOG updated its guidance in 2025: concurrent partner treatment may be considered for adults with recurrent symptomatic BV, and shared decision-making can be appropriate in other situations. Your partner needs individual clinical guidance; do not share prescriptions or assume that one metronidazole product alone reproduces the regimens studied.
Only if there is a valid, appropriately specified prescription and the pharmacy can lawfully dispense it. Clinical reassessment may be necessary.
No. Clinical guidelines and product-specific FDA labels have different roles; some regimens may involve off-label prescribing.
Seek reassessment for recurrent, persistent or worsening symptoms, especially fever, pelvic pain, pregnancy concerns or a change from the usual pattern.